Security key
38000Q201
Crescent Biopharma, Inc. - Ordinary Shares, par value $0.001 per share (CBIO)
CUSIP: 38000Q201
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Ordinary Shares, par value $0.001 per share
- Shares outstanding
- 13,839,146
- Total 13F shares
- 835,853
- Share change
- +461,357
- Total reported value
- $15,354,620
- Price per share
- $18.37
- Number of holders
- 3
- Value change
- +$8,475,128
- Number of buys
- 2
Report period
Q1 2026
Institutions
3
Top holders
3
CBIO full security history
Previous quarter: Q4 2025
CRESCENT BIOPHARMA, INC. SEC filings
CRESCENT BIOPHARMA, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 38000Q201
Recent filing periods:
Top shareholders of CBIO - Crescent Biopharma, Inc. - Ordinary Shares, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC |
13D/G
3/4/5
13F
|
Director, 10%+ Owner · Company |
19%
|
5,643,482
|
$73,252,396 | +$32,700,021 | 04 Dec 2025 | |
| FMR LLC |
13D/G
13F
|
Company |
15%
|
4,133,514
|
$49,932,849 | $0 | 31 Dec 2025 | |
| BVF INC/IL |
13F
|
Company |
10%
|
2,748,763
|
$32,600,329 | — | 31 Dec 2025 | |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
— |
9.5%
|
2,666,064
|
$29,460,007 | $0 | 31 Dec 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13D/G
13F
|
Company |
5.5%
|
1,510,033
|
$29,294,640 | $0 | 31 Mar 2026 | |
| VR Adviser, LLC |
13F
|
Company |
7.7%
|
2,133,576
|
$25,304,211 | — | 31 Dec 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13D/G
13F
|
Company |
4.2%
|
1,160,000
|
$22,504,000 | +$8,924,000 | 31 Mar 2026 | |
| ForGrowth III PA B.V. |
13D/G
|
— |
6.1%
|
1,677,852
|
$21,778,519 | $0 | 08 Dec 2025 | |
| 1Globe Capital LLC |
13D/G
|
— |
10%
|
1,425,432
|
$20,839,816 | +$7,729,886 | 07 Oct 2025 | |
| FCPM III SERVICES B.V. |
13F
|
Company |
6.1%
|
1,677,852
|
$19,899,325 | — | 31 Dec 2025 | |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
|
BVF PARTNERS L P/IL |
10%
|
1,387,863
|
$18,736,150 | $0 | 30 Jun 2025 | |
| Vestal Point Capital, LP |
13F
13D/G
|
Company |
5.4%
from 13D/G
|
1,500,000
|
$17,790,000 | — | 31 Dec 2025 | |
| Opaleye Management Inc. |
13F
|
Company |
4.3%
|
1,178,300
|
$13,974,638 | — | 31 Dec 2025 | |
| Logos Global Management LP |
13D/G
13F
|
Company |
4.1%
|
575,000
|
$7,762,500 | $0 | 30 Jun 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
2.2%
|
606,000
|
$7,187,160 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
2%
|
557,506
|
$6,612,021 | — | 31 Dec 2025 | |
| Boxer Capital Management, LLC |
13F
|
Company |
1.6%
|
453,686
|
$5,380,716 | — | 31 Dec 2025 | |
| Deep Track Capital, LP |
13F
|
Company |
1.6%
|
453,686
|
$5,380,716 | — | 31 Dec 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
1.6%
|
453,686
|
$5,380,716 | — | 31 Dec 2025 | |
| Scott D. Sandell |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,237,196
|
$5,279,783 | — | 25 Jan 2023 | |
| Joshua T. Brumm |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
503,984
mixed-class rows
|
$4,878,636 | — | 15 Dec 2025 | |
| NEXTBio Capital Management LP |
13F
|
Company |
1.4%
|
372,856
|
$4,422,072 | — | 31 Dec 2025 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
1.4%
|
372,856
|
$4,422,072 | — | 31 Dec 2025 | |
| Remedium Capital Partners, LLC |
13F
|
Company |
2.6%
|
361,250
|
$4,284,000 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.2%
|
338,125
|
$4,011,000 | — | 31 Dec 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.1%
|
302,457
|
$3,587,140 | — | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
1.1%
|
300,000
|
$3,558,000 | — | 31 Dec 2025 | |
| HEIGHTS CAPITAL MANAGEMENT, INC |
13F
|
Company |
0.96%
|
264,000
|
$3,131,040 | — | 31 Dec 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.96%
|
264,000
|
$3,108,992 | — | 31 Dec 2025 | |
| Jonathan McNeill |
3/4/5
|
President and COO |
—
mixed-class rows
|
237,736
mixed-class rows
|
$2,408,381 | — | 15 Dec 2025 | |
| Siren, L.L.C. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,589,064
|
$2,294,139 | — | 25 Jul 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.52%
|
143,412
|
$1,626,774 | — | 31 Dec 2025 | |
| Rachel K. King |
3/4/5
|
Director |
—
mixed-class rows
|
555,194
mixed-class rows
|
$1,545,582 | — | 01 May 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.45%
|
125,224
|
$1,485,157 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.4%
|
109,230
|
$1,295,468 | — | 31 Dec 2025 | |
| Invus Public Equities, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
6,317,565
|
$1,211,077 | — | 07 Aug 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.33%
|
91,079
|
$1,081,062 | — | 31 Dec 2025 | |
| Stonepine Capital Management, LLC |
13F
|
Company |
0.32%
|
87,682
|
$1,039,909 | — | 31 Dec 2025 | |
| Christopher Grant Doughty |
3/4/5
|
Chief Business Officer |
—
mixed-class rows
|
121,049
mixed-class rows
|
$937,885 | — | 15 Dec 2025 | |
| Blackstone Inc. |
13F
|
Company |
0.27%
|
75,614
|
$896,782 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.27%
|
74,000
|
$877,640 | — | 31 Dec 2025 | |
| John L. Magnani |
3/4/5
|
SVP of Research, CSO |
—
class O/S missing
|
370,923
|
$875,378 | — | 11 Nov 2022 | |
| Burkehill Global Management, LP |
13F
|
Company |
0.27%
|
74,000
|
$844,340 | — | 31 Dec 2025 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
0.23%
|
64,244
|
$761,934 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.22%
|
61,882
|
$733,921 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.21%
|
57,048
|
$676,589 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.17%
|
46,700
|
$553,862 | — | 31 Dec 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.12%
|
32,500
|
$385,450 | — | 31 Dec 2025 | |
| Chinmaya Rath |
3/4/5
|
SVP and Chief Business Officer |
—
mixed-class rows
|
411,178
mixed-class rows
|
$380,380 | — | 12 Jan 2024 | |
| Jan Pinkas |
3/4/5
|
Chief Scientific Officer |
—
mixed-class rows
|
92,532
mixed-class rows
|
$339,405 | — | 15 Dec 2025 |
Institutional Holders of Crescent Biopharma, Inc. - Ordinary Shares, par value $0.001 per share (CBIO) as of Q1 2026
As of 31 Mar 2026,
Crescent Biopharma, Inc. - Ordinary Shares, par value $0.001 per share (CBIO) was held by
3 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
835,853 shares.
The largest 3 holders included
Boxer Capital Management, LLC, Remedium Capital Partners, LLC, and Quadrature Capital Ltd.
This page lists
3
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
2
Q1 2026 holders
3
Holder diff
1
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.